? PLANNING AND EVALUATION The mission of Fox Chase Cancer Center (FCCC) is to prevail over cancer, marshaling heart and mind in bold scientific discovery, pioneering prevention, and compassionate care. In order to execute this mission, FCCC relies on a comprehensive Planning and Evaluation system that encompasses all Research Programs, Shared Resources, clinical departments, and administration. This structure monitors the Center?s progress relative to the Strategic Plan, the needs of the FCCC?TU catchment area, and the national cancer program.
The Specific Aims of FCCC?s Planning and Evaluation activity are to ensure effective and well-coordinated use of all Cancer Center Support Grant resources, institutional investment, and philanthropic funds in service of the Center?s mission; and to establish a direction for the Center?s Research Program development. Planning and Evaluation incorporates advice from the FCCC External Advisory Committee (EAC) and its Internal Advisory Committee (IAC), as well as from a multi-tiered leadership and governance structure. Fisher, as Cancer Center Director, has the authority and ultimate responsibility for execution of the strategic plan, organizing the Center, setting priorities for the development of new Research Programs and Shared Resources, recruiting and retaining junior scientists and academic leaders, dispensing developmental funds to junior faculty support and pilot grants, and optimizing space and resource utilization. He relies on Deputy Director and Chief Scientific Officer Chernoff and the other Deputy Directors (El-Deiry and Beck) to manage the various components of the Center and chair internal planning efforts. Fisher chairs the weekly Cancer Center Leadership Committee (CCLC), comprising the Deputy and Associate Directors, Vice President for Research Administration (VPRA) Gricoski, Research Program leaders and clinical department chairs. Ideas for recruitment, scientific initiatives and Shared Resources arise at the Program level, are brought to the CCLC for discussion and prioritization, then to biweekly meetings of the Deputy Directors, VPRA and Fisher. CCLC also reviews evaluative reports arising from Research Program retreats, EAC and IAC meetings, and the Facilities Parent Oversight Committee (Shared Resources). Reports from internal and external consulting groups are incorporated into strategic planning, generating a living and forward looking statement of Fox Chase?s direction and activities for the ensuing five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-52
Application #
9331451
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-08-01
Budget End
2018-07-31
Support Year
52
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Mortazavi, S M J; Bevelacqua, J J; Fornalski, K W et al. (2018) Comments on ""Space: The Final Frontier-Research Relevant to Mars"". Health Phys 114:344-345
Esposito, Andrew C; Crawford, James; Sigurdson, Elin R et al. (2018) Omission of radiotherapy after breast conservation surgery in the postneoadjuvant setting. J Surg Res 221:49-57
Dong, Yanqun; Zaorsky, Nicholas G; Li, Tianyu et al. (2018) Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer. J Med Imaging Radiat Oncol 62:116-121
Ge, Yunhui; Borne, Elias; Stewart, Shannon et al. (2018) Simulations of the regulatory ACT domain of human phenylalanine hydroxylase (PAH) unveil its mechanism of phenylalanine binding. J Biol Chem 293:19532-19543
Chow, H Y; Dong, B; Valencia, C A et al. (2018) Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun 9:3473
Egleston, Brian L; Pedraza, Omar; Wong, Yu-Ning et al. (2018) Temporal trends and characteristics of clinical trials for which only one racial or ethnic group is eligible. Contemp Clin Trials Commun 9:135-142
Golemis, Erica A; Scheet, Paul; Beck, Tim N et al. (2018) Molecular mechanisms of the preventable causes of cancer in the United States. Genes Dev 32:868-902
Reese, Jennifer Barsky; Sorice, Kristen; Lepore, Stephen J et al. (2018) Patient-clinician communication about sexual health in breast cancer: A mixed-methods analysis of clinic dialogue. Patient Educ Couns :
Wagner, Jessica; Kline, C Leah; Zhou, Lanlan et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. J Clin Invest 128:2325-2338
Araiza-Olivera, D; Feng, Y; Semenova, G et al. (2018) Suppression of RAC1-driven malignant melanoma by group A PAK inhibitors. Oncogene 37:944-952

Showing the most recent 10 out of 1280 publications